Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2016-01-06 | recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A | Immune Design (USA - MA) | soft tissue sarcoma | Granting of the orphan status in the US |
2016-01-13 | S-nitrosoglutathione reductase inhibitor | Nivalis Therapeutics (USA - CO) | cystic fibrosis |
Granting of the orphan status in the US |
2017-12-08 | latanoprostene bunod ophthalmic solution | Valeant Pharmaceuticals (Canada) |
|
Product launch |
2015-09-21 | metadoxine extended release (MDX) | Alcobra (Israel) | fragile X syndrome |
Granting of a Fast Track status |
2016-03-17 | MDXHealth (Belgium) | prostate cancer |
Product launch | |
2015-11-30 | Biocartis (Belgium) | detection of influenza virus and respiratory syncytial virus |
Product launch | |
2015-12-22 | Biocartis (Belgium) | melanoma |
Product launch | |
2015-12-22 | Biocartis (Belgium) | metastatic colorectal cancer (mCRC) mutation analysis |
Product launch | |
2016-08-12 | ephedrine sulfate | Flamel Technologies (France) | hypotension in surgical setting |
Product launch |
2016-06-09 | glutaminyl cyclase inhibitors | Probiodrug (Germany) | Alzheimer's disease, mild cognitive impairment |
Granting of a patent |
2016-02-17 | 1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one] | Allianz Pharmascience (USA - MD) | spinal and bulbar muscular atrophy |
Granting of the orphan status in the US |
2016-02-04 | afamelanotide | Clinuvel (Australia) | cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease) |
Granting of the orphan status in the US |
2016-02-08 | angiotensin (1-7) | Tarix Orphan (USA - MA) | LAMA2-related muscular dystrophy |
Granting of the orphan status in the US |
2016-02-23 | cannabidiol | Zynerba Pharmaceuticals (USA - PA) | Fragile X syndrome |
Granting of the orphan status in the US |
2016-02-18 | CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid | Bellicum Pharmaceuticals (USA - TX) | replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant |
Granting of the orphan status in the US |
2016-02-08 | dabrafenib | Novartis (Switzerland) |
|
Granting of the orphan status in the US |
2016-02-17 | dantrolene sodium | Washington University in St. Louis (USA - MI) | Wolfram syndrome |
Granting of the orphan status in the US |
2016-02-11 | dodecafluoropentane emulsion | NuvOx Pharma (USA - AZ) | sickle cell disease |
Granting of the orphan status in the US |
2016-08-03 | Avacta (UK) | Granting of a patent | ||
2016-02-08 | eltoprazine HCl | Amarantus BioScience (USA – CA) | levodopa-induced dyskinesia associated with Parkinson's disease |
Granting of the orphan status in the US |
© 2024 Biopharmanalyses - Powered by Samacom+